Sono molti anni che si esegue la terapia con psoraleni più esposizioni alle radiazioni ultraviolette A, e nonostante la loro discreta tossicità si continuano ad eseguire. Finalmente un bel lavoro pubblicato dalla prestigiosa rivista scientifica Archives of Dermatology mette in cantina questa metodica considerandola assolutamente inferiore agli ultravioletti B a 311 nanometri (UVB-NB) senza farmaci aggiunti.
La terapia con soli UVB-NB è considerata attualmente in assoluto la migliore e anche se non sarà risolutiva per tutti comunque è un bel passo avanti rispetto a qualsiasi altra terapia.
Ricordiamo a tutti che è possibile sottoporsi a terapia con UVB-NB solo sotto stretto controllo medico.

Ecco l'articolo in inglese (l'abstract)  

Arch Dermatol. 2007 May;143(5):578-584.

Randomized Double-blind Trial of Treatment of Vitiligo: Efficacy of Psoralen-UV-A Therapy vs Narrowband-UV-B Therapy.

Yones SS, Palmer RA, Garibaldinos TM, Hawk JL.

 Dip Der, FCD, Photobiology Unit, Second Floor, St John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Guy’s, King's and St Thomas' School of Medicine, King's College, London SE1 7EH, England. Questo indirizzo e-mail è protetto dallo spam bot. Abilita Javascript per vederlo. .

 OBJECTIVE: To compare the efficacy of oral psoralen-UV-A (PUVA) with that of narrowband-UV-B (NB-UVB) phototherapy in patients with nonsegmental vitiligo. DESIGN: Double-blind randomized study. SETTING: Phototherapy unit in a university hospital. Patients Fifty-six patients with nonsegmental vitiligo. Interventions Twice-weekly therapy with PUVA or NB-UVB. MAIN OUTCOME MEASURES: The change in body surface area affected by vitiligo and the color match of repigmented skin compared with unaffected skin were assessed after 48 sessions of therapy, at the end of the therapy course, and 12 months after the end of therapy. RESULTS: The results in the 25 patients each in the PUVA and NB-UVB groups who began therapy were analyzed. The median number of treatments was 47 in the PUVA-treated group and 97 in the NB-UVB-treated group (P = .03); we suspect this difference was because of the differences in efficacy and adverse effects between the 2 modalities, such that patients in the NB-UVB group wanted a longer course of treatment. At the end of therapy, 16 (64%) of 25 patients in the NB-UVB group showed greater than 50% improvement in body surface area affected compared with 9 (36%) of 25 patients in the PUVA group. The color match of the repigmented skin was excellent in all patients in the NB-UVB group but in only 11 (44%) of those in the PUVA group (P<.001). In patients who completed 48 sessions, the improvement in body surface area affected by vitiligo was greater with NB-UVB therapy than with PUVA therapy (P = .007). Twelve months after the cessation of therapy, the superiority of NB-UVB tended to be maintained. Conclusion In the treatment of nonsegmental vitiligo, NB-UVB therapy is superior to oral PUVA therapy.